T-Cell-MMP Multimeric Polypeptide Epitope Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating T-cell activity are limited in their ability to achieve epitope-specific targeting and delivery of immunomodulatory peptides or chemotherapeutic agents, often relying on non-specific binding and lacking efficient mechanisms for stabilization during intracellular trafficking.
Innovation Solution
Development of T-cell modulatory multimeric polypeptides (T-Cell-MMPs) with chemical conjugation sites that allow for the specific binding of epitopes and payloads, incorporating immunomodulatory peptides and chemotherapeutic agents, and stabilization modifications such as disulfide linkages to enhance stability and targeting specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If non-specific binding methods are used for T-cell modulation, then ease of operation is improved, but manufacturing precision and targeting specificity deteriorate
Solution Approach 1:
The T-cell modulatory multimeric polypeptide is segmented into distinct functional domains: MHC class I molecules for epitope presentation, immunomodulatory peptides for T-cell activation/inhibition, and chemical conjugation sites for epitope attachment. This segmentation enables specific epitope-targeted T-cell modulation while maintaining operational simplicity through modular design.
Solution Approach 2:
The multimeric polypeptide structure integrates multiple functions into a single construct: antigen presentation via MHC class I, T-cell modulation through immunomodulatory peptides, and epitope-specific targeting via chemical conjugation sites. This multi-functionality achieves high targeting precision without compromising ease of operation.
2Device complexity
If conventional T-cell modulation methods are used, then device complexity is reduced, but reliability and stabilization during intracellular trafficking deteriorate
Solution Approach 1:
The invention employs a composite multimeric polypeptide structure combining MHC class I molecules, immunomodulatory peptides, and chemical conjugation sites. This composite design enhances stability during intracellular trafficking and presentation while maintaining controlled complexity through defined molecular architecture.
Solution Approach 2:
Instead of using complex cellular machinery for stable antigen presentation, the invention inverts the approach by engineering stable MHC class I multimeric constructs that inherently maintain stability during trafficking and presentation, simplifying the overall system while improving reliability.
3Manufacturing precision
If specific epitope targeting is implemented, then manufacturing precision is improved, but device complexity increases
Solution Approach 1:
The multimeric polypeptide incorporates local chemical conjugation sites with specific chemical properties (e.g., maleimide groups for cysteine conjugation) that enable site-specific epitope attachment. This local quality enhancement achieves high manufacturing precision for epitope targeting without requiring complex overall device architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
T-Cell-MMPs enable epitope-specific modulation of T-cell activity, facilitating targeted immune responses and the delivery of therapeutic agents, with enhanced stability and specificity, thereby improving therapeutic outcomes.
Implementation Method 1
insertion of cysteine residues that result in the formation of disulfide linkages linking the indicated regions of those helices
Implementation Method 2
engagement of the T-cell receptor (TCR), present on the surface of a T-cell, with a small peptide antigen non-covalently presented on the surface of an antigen presenting cell (APC) by a major histocompatibility complex (MHC)
Data Source
AI summary
The present disclosure provides T-cell modulatory multimeric polypeptides (“T-Cell-MMPs”) comprising an immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”) and a location for covalently attaching a molecule that can serve as an epitope, such as an epitope peptide. Once the epitope molecule is attached the resulting T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in an epitope selective/specific manner, and accordingly, for modulating an immune response in an individual.